Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

  Homepage
Continue on the current website:  

 

IB DCE

Performs post-processing of dynamically acquired MR datasets to evaluate image intensity variations over time

Inquire Now

Imaging
  • Ktrans
  • Ve
  • Vp
  • VIF

IB DCE generates dynamic contrast enhancement (DCE) parametric images.

These include the Ktrans transfer constant; extravascular, extra-cellular fractions (ve); and blood plasma fraction (vp).

yellow arrow

~29% improved nodule detection

American Journal of Roentgenology. 2018;210: 480-488. 10.2214/AJR.17.18718

yellow arrow

26% faster nodule search time

American Journal of Roentgenology. 2018;210: 480-488. 10.2214/AJR.17.18718

yellow arrow

Reduce interoperator variability with ClearRead CT Detect

Manual nodule detection is a task associated with interoperator variability. With ClearRead CT Detect, interreaderagreement is improved.

    References

    1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

    2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

    Legal Mentions

    1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

    2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

     

      DCE Perfusion Weighted MR Imaging (DCE-MRI)

      DCE Perfusion Weighted MR Imaging (DCE-MRI)

      Produces various parameter maps including: K: Transfer constant; IS: Initial Slope (aka Wash-In); WO: Wash­ Out; PE: Peak enhancement; IAUC: Initial Area Under the Curve; TTP: Time-to-Peak; rTTP: Relative Time-to­ Peak

      References

      References

      1. IB Clinic 2.0 release 21.12 User Manual
      2. Prah et al, Repeatability of Standardized and Normalized Relative CBV, AJNR Am J Neuroradiology, 2015
      3. Hu, et al, Impact of Software Modeling on the Accuracy of Perfusion MRI, AJNR Am J Neuroradiology, 2015
      4. Schmainda et al, Quantitative Delta T1 (dT1), AJNR Am J Neuroradiology, 2019
      5. Schmainda, Diffusion­ weighted MRI as a biomarker for treatment response in glioma, CNS Oncol, 2012

      What Customers Are Saying

      We appreciate the speed of IB products and their compatability with PACS. More recently, we have started to use IB products for image-guided surgical planning. We anticipate their use for radiation therapy planning in the near future. Our neurosurgeons,radiation oncologists, and neuro oncologists find perfusion scans and Delta T1 maps of the brain to be very useful, and now routinely write orders to obtain this information.

      Dr. Scott Rand
      MD PhD Professor of Radiology at Froedtert Health and the Medical College of Wisconsin.

      May not reflect a typical user experience; actual results may vary.

      Request a demo

      See Ahead for Yourself

      Inquire now
      LinkedIn LinkedIn

      © 2022, 2023 Bayer

      The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

      BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. Other trademarks and company names mentioned herein are properties of their respective owners.

      This is intended to provide information for healthcare professionals and other relevant decision makers in the US. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

       

      Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information.

       

      You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

      Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

       

      Last Updated: August 2023

      © 2022, 2023, 2024 Bayer

      The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

      BAYER, the Bayer Cross, Radimetrics and Calantic are trademarks owned by Bayer and/or registered in the U.S. Other trademarks and company names mentioned herein are properties of their respective owners.

      This is intended to provide information for healthcare professionals and other relevant decision makers in the US. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

       

      Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information.

       

      You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

      Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

       

      Bayer U.S. | Digital Solutions, 100 Bayer Blvd., Whippany, NJ 07981-0915

       

      Last Updated: March 2024